

Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies

Joseph P Gaut^{1,2}, Sanjay Jain^{1,2}, John D Pfeifer¹, Katinka A Vigh-Conrad¹, Meagan Corliss¹, Mukesh K Sharma¹, Jonathan W Heusel^{1,3} and Catherine E Cottrell^{1,3,4}

¹Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, St Louis, MO, USA; ²Department of Medicine, Washington University School of Medicine, Renal Division, St Louis, MO, USA; ³Department of Genetics, Washington University School of Medicine, St Louis, MO, USA and ⁴Institute for Genomic Medicine, Nationwide Children's Hospital, St Louis, MO, USA

Next-generation sequencing is increasingly used for clinical evaluation of patients presenting with thrombotic microangiopathies because it allows for simultaneous interrogation of multiple complement and coagulation pathway genes known to be associated with disease. However, the diagnostic yield is undefined in routine clinical practice. Historic studies relied on case–control cohorts, did not apply current guidelines for variant pathogenicity assessment, and used targeted gene enrichment combined with next-generation sequencing. A clinically enhanced exome, targeting ~54 Mb, was sequenced for 73 patients. Variant analysis and interpretation were performed on genes with biological relevance in thrombotic microangiopathy (*C3*, *CD46*, *CFB*, *CFH*, *CFI*, *DGKE*, and *THBD*). *CFHR3-CFHR1* deletion status was also assessed using multiplex ligation-dependent probe amplification. Variants were classified using American College of Medical Genetics and Genomics guidelines. We identified 5 unique novel and 14 unique rare variants in 25% (18/73) of patients, including a total of 5 pathogenic, 4 likely pathogenic, and 15 variants of uncertain clinical significance. Nine patients had homozygous deletions in *CFHR3-CFHR1*. The diagnostic yield, defined as the presence of a pathogenic variant, likely pathogenic variant or homozygous deletion of *CFHR3-CFHR1*, was 25% for all patients tested. Variants of uncertain clinical significance were identified in 21% (15/73) of patients. These results illustrate the expected diagnostic yield in the setting of thrombotic microangiopathies through the application of standardized variant interpretation, and highlight the utility of such an approach. Sequencing a clinically enhanced exome to enable targeted, disease-specific variant analysis is a viable approach. The moderate rate of variants of uncertain clinical significance highlights the paucity of data surrounding the variants in our cohort and illustrates the need for expanded variant curation resources to aid in thrombotic microangiopathy-related disease variant classification. *Modern Pathology* (2017) 30, 1739–1747; doi:10.1038/modpathol.2017.90; published online 28 July 2017

Thrombotic microangiopathies, defined by microangiopathic hemolytic anemia, microvascular thrombosis, and organ damage, are a diverse group of disorders with varied etiologies.^{1,2} Atypical hemolytic uremic syndrome is an event-triggered thrombotic microangiopathy due to overactivation of the

alternative complement pathway predominantly involving the kidneys.^{1,3} Hereditary and acquired genetic variants in the alternative complement and coagulation pathways have been identified in association with disease.^{1,4–9} Owing to the ability to evaluate multiple genes simultaneously for known and novel mutations, massively parallel or 'next-generation' sequencing is poised to have a critical role in identifying patients with thrombotic microangiopathy-related genetic variants that have implications for diagnosis, therapy, and prognosis.^{3,7,10–14} Clinical practice guidelines recommend genetic testing for all patients presenting with atypical hemolytic uremic syndrome to guide prognosis and treatment.^{15–17}

Correspondence: Assistant Professor JP Gaut, MD, PhD, Department of Pathology and Immunology, Division of Anatomic and Molecular Pathology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, MO 63110-1093, USA.

E-mail: jpgaut@wustl.edu

Received 31 March 2017; revised 24 May 2017; accepted 25 May 2017; published online 28 July 2017

Historically, when a genetic etiology was considered, single-gene analysis was used to identify variants associated with clinical phenotypes. As the number of causative genes grows, this iterative process becomes costly and time-consuming. The advent of rapid, economical, and efficient next-generation sequencing technologies has revolutionized medical practice. Since completion of the initial draft of the human genome in 2000, the cost and time required to sequence the human genome have decreased markedly.¹⁸ Additional improvements in accuracy and automation allowed next-generation sequencing to become a widespread clinical diagnostic tool for pathogenic variant detection. Several reports described the utility of targeted gene enrichment combined with next-generation sequencing in renal disease evaluation.^{14,19–23} Using this approach, investigators reported a positive genetic diagnosis in 43–61% of patients sequenced for atypical hemolytic uremic syndrome.^{3,4,7,24} However, none of these studies used application of current variant interpretation standards as defined by the American College of Medical Genetics and Genomics/American Molecular Pathology Association (ACMG/AMP).²⁵

The development of the clinical exome holds significant promise for genetic testing in patients with constitutional disease. The clinical research exome has become a dominant exome-capture reagent for clinical next-generation sequencing in the assessment of constitutional disease because it

provides enrichment for more than 4600 genes known to be associated with complex and Mendelian disease as curated from databases including Online Mendelian Inheritance in Man, ClinVar, and the Human Gene Mutation Database. This represents a cost-effective technique for the generation of hundreds of disease-specific gene panels that is readily adaptable as clinical knowledge advances. With approved human research protocols, variants across the exome may be evaluated for discovery and other clinical research investigations. To our knowledge, no prior studies have used clinical exome sequencing followed by targeted, disease-specific bioinformatic analysis and reporting in the evaluation of patients with thrombotic microangiopathies.

This study is the first to report the diagnostic yield of next-generation sequencing testing using a clinical exome-based strategy and rigorous application of current clinical variant interpretation standards for patients with thrombotic microangiopathies in routine clinical practice. Our results demonstrate that this approach identifies a genetic cause, defined as identification of pathogenic variants or likely pathogenic variants in 12% of all patients referred for thrombotic microangiopathy genetic testing. The diagnostic yield increases to 25% by including detection of homozygous deletion of *CFHR3-CFHR1*. This is significant as most cases in this cohort referred for clinical sequencing represent singletons with little clinical data provided.

Materials and methods

Laboratory Workflow

This study was granted exempt status from the Washington University School of Medicine institutional review board. All tests were requested by licensed physicians (Figure 1). The data presented represent consecutive samples submitted to Genomics and Pathology Services at Washington University in Saint Louis (GPS@WUSTL) between 1 February 2015 and 29 February 2016. The laboratory is College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Test methodology was twofold, encompassing both next-generation sequencing for genetic variant detection, and multiplex ligation-dependent probe amplification for detection of deletion of *CFHR1-CFHR3*. The submitted specimen for testing represented 2–5 ml of peripheral blood obtained in a lavender-top EDTA tube with genomic DNA extracted manually using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). Deletion analysis was performed on extracted DNA as a send-out test to Cincinnati Children's Hospital. Briefly, oligonucleotide probes hybridize adjacent regions of the *CFHR1* and *CFHR3* genes. Only probes that are adjacently hybridized are able to be ligated,




Figure 1 Flow chart depicting the thrombotic microangiopathy genetic testing results by the number of patients with variants, variant interpretation, and variant distribution among complement and coagulation pathway genes. TMA, thrombotic microangiopathy; VUS, variant of uncertain clinical significance.

amplified, and quantified using capillary electrophoresis. In the presence of *CFHR1-CFHR3* deletions, probe amplification will be diminished or absent.^{26,27} Library preparation for the next-generation sequencing assay began by fragmenting DNA to ~200 bp by ultrasonication, followed by end repair, A-tailing, and ligation to sequencing adapters. Target capture was performed using the SureSelectXT Clinical Research Exome (Agilent Technologies, Santa Clara, CA) encompassing 54 Mb of target space. Libraries were sequenced using an Illumina HiSeq2500 (Illumina, San Diego, CA) with paired 2 × 101-bp reads. Analytic sensitivity, specificity, and reproducibility were established per the CAP next-generation sequencing-testing checklist.²⁸

Variant Annotation and Reporting

Variant classifications were based on standards and guidelines presented as a joint consensus recommendation published by the American College of Medical Genetics and Genomics and the Association of Molecular Pathology.²⁵ Variant calls were reported using Human Genome Variation Society nomenclature (<http://www.hgvs.org/mutnomen>), and variant attributes were examined using sequence variation databases including the Exome Aggregation Consortium (ExAC) (exac.broadinstitute.org, encompassing data from the 1000 Genomes project, and NHLBI-GO Exome Sequencing Project, among others, along with annotated data from the Single-Nucleotide Polymorphism Database (v135) (<http://www.ncbi.nlm.nih.gov/projects/SNP/>)), the FH atypical hemolytic uremic syndrome mutation database (<http://www.fh-hus.org/>), ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>), the HGMD public resource (<http://www.hgmd.cf.ac.uk/ac/index.php>), and an internally curated clinical-grade database of variants and interpretations housed in the Clinical Genomicist Workspace (PierianDx, St Louis, MO).^{29,30} Variants were classified on the basis of the sum of evidence surrounding the genomic alteration: level 1-pathogenic, level 2-likely pathogenic, level 3-variant of uncertain significance, level 4 likely benign, and level 5-benign.²⁵ All results were reviewed by a pathologist with subspecialty boards in Molecular Genetics from the American Board of Pathology, or a clinical laboratory geneticist certified in Clinical Molecular Genetics and Clinical Cytogenetics from the American Board of Medical Genetics and Genomics before release to the patient's medical record.

Statistics

Statistical analyses were performed using the GraphPad Software. Categorical variables were examined using the Fisher's exact test, two-tailed. Continuous variables were evaluated using a Mann-Whitney test.

Results

Assay Design and Validation

The thrombotic microangiopathy genetic test is performed using the Agilent SureSelectXT Clinical Research exome with the reported gene set encompassing *CFH*, *CFI*, *CFB*, *C3*, *CD46*, *DGKE*, and *THBD*. In total, the capture reagent targets ~54 Mb of exonic and selected intronic regions for sequencing. Bioinformatic filtering is used to restrict the analyzed and reported gene set. Validation was performed using 28 genomic DNA samples including 3 HapMap cell lines provided by the National Institute of General Medical Sciences-Coriell cell repositories, 5 blinded peripheral blood samples from individuals without a history of renal disease, 17 blinded patient samples harboring at least one known pathogenic genetic variant, a single unblinded patient sample, and 2 production patient samples. All analyses were based on human reference sequence UCSC build hg19; NCBI build 37.2. Analytic sensitivity, specificity, and positive predictive value to detect single base pair variation in coding regions throughout the entire Agilent SureSelectXT Clinical Research exome were ~96.6%, 100.0%, and 99.3%, respectively, as determined by comparison of genetic sequence called by this assay using HapMap DNA sample NA12878 to the high-confidence genotypes reported at those positions by Complete Genomics (<http://www.completegenomics.com>). Analysis of the subset of thrombotic microangiopathy disease-associated genes showed sensitivity, specificity, and positive predictive value, all approaching 100%. Single-nucleotide variants and small insertion/deletion events were called using SAMtools mpileup.^{31,32}

Patient Characteristics

Seventy-three patients underwent exome-based thrombotic microangiopathy genetic testing. The demographic characteristics are summarized in Table 1. The average age at the time of testing was 36.7 ± 16.5 years. Forty-six females and 27 males were tested. Patients were classified based on the referring clinician's clinical diagnosis, which included 61 atypical hemolytic uremic syndrome, 4 thrombotic thrombocytopenic purpura, and 8 thrombotic microangiopathy.

Variant Interpretation

Before variant calling and interpretation, all samples underwent detailed quality control analysis.²⁸ A quality control metrics report is generated detailing the total number of reads, percent mapped to the genome, on-target, on-target unique, mean mapping quality, and depth of coverage. Genomic positions failing to meet a coverage depth of at least 10x, or those failing to meet a variant quality call of 30, were

Table 1 Patient demographics

Diagnosis	Number of patients	Age (years)	Gender	Race
aHUS/HUS	61	35.5 ± 16.2	22M:39F	37 Caucasian 5 Hispanic 6 African American 4 Asian 1 Mediterranean 3 Mixed 5 Unknown
TTP	4	47.8 ± 3.3	2M:2F	3 Caucasian 1 African American
TMA	8	40.9 ± 21	3M:5F	5 Caucasian 1 Hispanic 1 African American 1 Asian
All patients	73	36.7 ± 16.5	27M:46F	45 Caucasian 6 Hispanic 8 African American 5 Asian 1 Mediterranean 3 Mixed 5 Unknown

Abbreviations: aHUS, atypical hemolytic uremic syndrome; HUS, hemolytic uremic syndrome; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.

filtered out of analysis. All variants were initially filtered for a population minor allele frequency < 5%; this cutoff was chosen as this represents stand-alone evidence for a benign classification according to ACMG/AMP guidelines.²⁵ All variants with a minor allele frequency < 5% were analyzed and scored as pathogenic, likely pathogenic, uncertain clinical significance, likely benign, or benign based on the scheme outlined by the ACMG/AMP.²⁵ To facilitate classification, a variant assessment worksheet with the ACMG/AMP criteria is used for each variant and archived as part of the permanent testing record.

Genetic Variants

The genetic variants are summarized in Table 2. Of the 73 patients sequenced, 27% (20/73) harbored 24 variants classified as variants of uncertain clinical significance, pathogenic, or likely pathogenic, and 12% (9/73) had homozygous deletions in *CFHR3-CFHR1*. Among the 24 single-nucleotide variants are 5 pathogenic variants, 4 likely pathogenic variants, and 15 variants of uncertain clinical significance (Figure 1). Six variants (5 of which are unique) are

novel, having not been reported in the literature or deposited in existing population or disease-associated variant databases (ExAC, NHLBI, FH-aHUS, dbSNP). Details of the pathogenic/likely pathogenic variants are summarized in Table 3 and variants of uncertain clinical significance are summarized in Table 4. Six patients carried multiple genomic alterations: greater than one single-nucleotide variant and/or harboring a homozygous *CFHR3-CFHR1* deletion (Figure 2). The patients identified with pathogenic or likely pathogenic variants tended to be younger at the time of testing, 29.2 ± 14.5 years compared with 37.8 ± 16.6 years. However, this difference was not statistically significant.

Uniquely occurring pathogenic and likely pathogenic variants ($n=8$) classified by the ACMG/AMP criteria were compared with unique variants of uncertain clinical significance ($n=12$) classified using the same criteria. Pathogenic and likely pathogenic variants tended to have lower minor allele frequencies across all populations based on the ExAC database, $1.11e-05 \times 2.18e-05$ compared with variants of uncertain clinical significance, $7.35e-04 \times 1.32e-03$ ($P=0.11$).³⁰ The genomic evolutionary rate profiling (GERP++) scores quantifying evolutionary constraint differed significantly between the variant classifications, 4.17 ± 1.86 for pathogenic/likely pathogenic versus -0.16 ± 3.73 for variants of uncertain clinical significance ($P=0.004$).³³ *In silico* prediction tools were compared for the missense variants classified as pathogenic/likely pathogenic ($n=4$) and variants of uncertain clinical significance ($n=12$). SIFT (release 63), PolyPhen-2 (version 2.2.2, r394), and the protein variation effect analyzer (PROVEAN, version 1.1.5) algorithms showed statistically significant differences between the pathogenic/likely pathogenic variants compared with variants of uncertain clinical significance, -1.80 ± 2.10 ($P=0.001$, $P=0.03$, and $P=0.004$, respectively).³⁴

CFH and *CD46* were most commonly identified as harboring single-nucleotide variants, each occurring in 7% (5/73) of patients (Figures 1 and 2). The five patients with *CFH* variants had four distinct single-nucleotide variants, three classified as variants of uncertain clinical significance and one as pathogenic (Tables 3 and 4). Two were reported previously.^{24,35-39} One patient with the p.Q950H variant of uncertain clinical significance also showed homozygous deletion of *CFHR3-CFHR1*. Two related patients carrying the p.G918E *CFH* variant also harbored the c.287-2A>G splice-site pathogenic variant in *CD46*. *CD46* contained four distinct variants (Figures 1 and 2). Of the four variants, two were classified as pathogenic, one likely pathogenic, and one of uncertain clinical significance (Tables 3 and 4).

Three distinct variants were found in *CFI*, one likely pathogenic and two of uncertain clinical significance (Figure 2 and Table 3). The two variants of uncertain clinical significance have been reported

Table 2 Genetic variants meeting criteria for pathogenic, likely pathogenic, or VUS identified in patients referred for TMA genetic testing

Patient	Gene	Interpretation	Variant (coding)	Variant (genomic)	Type	Clinical diagnosis
65	<i>C3</i>	LP	p.R1042L	Chr19:g.6694471C>A	Missense	aHUS
7	<i>C3</i>	LP	p.R161W	Chr19:g.6718128G>A	Missense	aHUS
3	<i>C3</i>	VUS	p.T647M ^a	Chr19:g.6707846G>A	Missense	aHUS
40	<i>C3</i>	VUS	p.Q185H	Chr19:g.6714407C>G	Missense	aHUS
80	<i>C3</i>	VUS	p.T1383N	Chr19:g.6684423G>T	Missense	aHUS
78	<i>C3</i>	VUS	p.E1636G	Chr19:g.6677978T>C	Missense	aHUS
12	<i>CD46</i>	P	c.287-2A>G	Chr1:g.207930883A>G	Splice site	HUS
35	<i>CD46</i>	P	c.287-2A>G	Chr1:g.207930883A>G	Splice site	Postpartum TMA
25	<i>CD46</i>	P	c.1127+2T>G ^a	Chr1:g.207959029T>G	Splice site	TTP
5	<i>CD46</i>	LP	p.C35Y	Chr1:g.207930365G>A	Missense	HUS
38	<i>CD46</i>	VUS	p.P324L	Chr1:g.207943690C>T	Missense	aHUS s/p renal transplant
21	<i>CFH</i>	P	c.619+1G>A ^a	Chr1:g.196646798G>A	Splice site	aHUS
84	<i>CFH</i>	VUS	p.I372V ^a	Chr1:g.196658699A>G	Missense	TMA, loss of two kidney transplants
31	<i>CFH</i>	VUS	p.Q950H	Chr1:g.196709816G>T	Missense	aHUS
12	<i>CFH</i>	VUS	p.G918E ^a	Chr1:g.196706761G>A	Missense	HUS
35	<i>CFH</i>	VUS	p.G918E ^a	Chr1:g.196706761G>A	Missense	Postpartum TMA
69	<i>CFI</i>	LP	p.I370N ^a	Chr4:g.110670413A>T	Missense	aHUS
30	<i>CFI</i>	VUS	p.I306V	Chr4:g.110673648T>C	Missense	HUS
45	<i>CFI</i>	VUS	p.D403N	Chr4:g.110667600C>T	Missense	aHUS
79	<i>DGKE</i>	P	p.W322*	Chr17:g.54926134G>A	Nonsense	aHUS
27	<i>THBD</i>	VUS	p.P495S	Chr20:g.23028659G>A	Missense	HUS
79	<i>THBD</i>	VUS	p.A43T	Chr20:g.23030015C>T	Missense	aHUS
42	<i>THBD</i>	VUS	p.A43T	Chr20:g.23030015C>T	Missense	aHUS
65	<i>THBD</i>	VUS	p.A43T	Chr20:g.23030015C>T	Missense	aHUS

Abbreviations: aHUS, atypical hemolytic uremic syndrome; HUS, hemolytic uremic syndrome, LP, likely pathogenic, P, pathogenic, TMA, thrombotic microangiopathy; VUS, variant of uncertain clinical significance.

^aNovel variant.

Table 3 Pathogenic and likely pathogenic variants

Diagnosis	Gene	Variant (coding)	SIFT	PolyPhen	PROVEAN	MAF ^a	GERP	dbSNP	Human Splicing Finder
HUS and TMA	<i>CD46</i>	c.287-2A>G	N/A	N/A	N/A	3.121e-05	4.07	No	Positive ^b
TMA	<i>CD46</i>	c.1127+2T>G ^c	N/A	N/A	N/A	0	2.96	No	Positive ^b
HUS	<i>CD46</i>	p.C35Y	0	1	-10.16	0	3.72	No	N/A
aHUS	<i>CFH</i>	c.619+1G>A ^c	N/A	N/A	N/A	0	5.21	No	Positive ^b
aHUS	<i>CFI</i>	p.I370N ^c	0	0.998	-6.09	0	5.71	No	N/A
HUS	<i>C3</i>	p.R161W	0.001	0.952	-5.06	0	0.356	No	N/A
aHUS	<i>C3</i>	p.R1042L	0	0.996	-6.16	0	5.76	No	N/A
aHUS	<i>DGKE</i>	p.W332 ^a	N/A	N/A	N/A	5.766e-05	5.59	Rs138924661	N/A

Abbreviations: aHUS, atypical hemolytic uremic syndrome; ExAC, Exome Aggregation Consortium; MAF, minor allele frequency; N/A, not applicable; TMA, thrombotic microangiopathy.

^aRefers to the overall MAF in the ExAC database.

^bAlteration of wild-type acceptor site, most probably affecting splicing.

^cNovel variant.

previously.^{40,41} The patient with the previously reported p.I306V variant also harbored a homozygous deletion in *CFHR3-CFHR1*.

Six distinct variants were identified in *C3*, two likely pathogenic and four variants of uncertain clinical significance (Figure 2 and Table 4). Five were previously reported in the literature and/or the FH atypical hemolytic uremic syndrome database.^{4,24,42} One patient with a likely pathogenic variant, p.R1042L, also carried the p.A43T variant of uncertain clinical significance in *THBD*.

THBD harbored variants in four patients (Figure 2). Three patients carried the p.A43T variant and one carried the p.P495S variant, both of uncertain clinical significance. Both variants have been

previously reported and have low minor allele frequency (<0.4%).⁴³ As mentioned previously, one patient with a p.A43T variant also harbored a likely pathogenic variant in *C3*. Another patient with the p.A43T variant carried a pathogenic variant in *DGKE*.

The only variant identified in *DGKE*, p.W322*, has been previously described in the literature as pathogenic (Figure 2 and Tables 2 and 3).⁴⁴

Diagnostic Yield

Current ACMG/AMP guidelines indicate that variants classified as of uncertain clinical significance are not to be used in clinical decision making.²⁵

Table 4 Variants of uncertain clinical significance

Disease	Gene	Variant (coding)	SIFT	PolyPhen	PROVEAN	MAF ^a	GERP	dbSNP
aHUS	<i>CD46</i>	p.P324L	0.094	0.998	-2.10	0.0006365	-0.557	Rs41317833
TMA	<i>CFH</i>	p.I372V ^b	0.025	0.981	-0.72	Not present	-7.48	No
aHUS	<i>CFH</i>	p.Q950H	0.006	0.986	-2.98	0.003583	-4.92	Rs149474608
HUS and TMA	<i>CFH</i>	p.G918E ^{b, c}	0.042	0.992	-5.90	Not present	6.04	No
HUS	<i>CFI</i>	p.I306V	0.458	0.012	0.08	0.0004798	-2.55	Rs113273712
aHUS	<i>CFI</i>	p.D403N	1	0.003	1.45	2.48e-05	0.0847	Rs139881195
HUS	<i>C3</i>	p.T647M ^b	0.018	0.321	-1.13	Not present	2.63	No
aHUS	<i>C3</i>	p.Q185H	0.065	0.033	-1.36	Not present	-1.4	No
aHUS	<i>C3</i>	p.T1383N	0.036	0.63	-1.62	9.06e-05	1.59	Rs139100972
aHUS	<i>C3</i>	p.E1636G	0.002	0.967	-5.55	Not present	3.95	No
HUS	<i>THBD</i>	p.P495S	0.146	0.273	-2.74	0.000575	-0.884	Rs1800578
aHUS x 3 patients	<i>THBD</i>	p.A43T	0.533	0.002	-0.39	0.00343	1.61	Rs1800576

Abbreviations: aHUS, atypical hemolytic uremic syndrome; ExAC, Exome Aggregation Consortium; HUS, hemolytic uremic syndrome; MAF, minor allele frequency; TMA, thrombotic microangiopathy.

^aRefers to the overall MAF in the ExAC database.

^bNovel variant.

^cIdentified in association with a pathogenic variant in *CD46*.




Figure 2 Summary of thrombotic microangiopathy genetic testing results. Patients are grouped according to clinical diagnosis. Genes are grouped according to function. Age represents the age at the time of testing. A, Asian, AA, African American; aHUS, atypical hemolytic uremic syndrome, CA, Caucasian; H, Hispanic; HUS, hemolytic uremic syndrome; NA, Native American; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura; Unk, unknown; VUS, variant of uncertain clinical significance.

Therefore, these are not considered a positive genetic diagnosis in this study for purposes of measuring clinical utility or diagnostic yield. In patients with a clinical diagnosis of thrombotic microangiopathy, atypical hemolytic uremic syndrome, hemolytic uremic syndrome, or thrombotic thrombocytopenic

purpura ($n=73$), 9 had pathogenic or likely pathogenic variants, and 9 had homozygous deletions of *CFHR3-CFHR1*, representing a diagnostic yield of 25% (18/73). Isolated variants of uncertain clinical significance were identified in 10 (14%) patients.

Discussion

We report our 1-year experience using exome-based next-generation sequencing in routine diagnostic evaluation of patients referred for thrombotic microangiopathy genetic testing. Our results showed pathogenic or likely pathogenic variants in 12% (9/73) and variants of uncertain clinical significance in 21% (15/73) of all patients tested. This is comparable to the rate of pathogenic and likely pathogenic variants identified in a previous large series of patients sequenced for thrombotic microangiopathy.³ In that particular study, 193 patients were sequenced, and 23 pathogenic or likely pathogenic variants were identified for a diagnostic yield of 12%.³ In our current study, when homozygous deletions of *CFHR3-CFHR1* are included, the overall diagnostic yield increases to 21%. Similarly, in the large series by Bu *et al.*,³ including the rate of homozygous deletions of *CFHR3-CFHR1* increases their diagnostic yield to 21%. The current study shows that exome-based, targeted next-generation sequencing in a CAP/CLIA-certified laboratory is an efficient and reliable approach for the identification of diagnostic variants in patients with thrombotic microangiopathy. The positive diagnostic rate is comparable to a similar series that used non-exome-based next-generation sequencing techniques.³

Genetic sequencing has the potential to uncover single-nucleotide variants of clinical significance that have not been previously described in the literature or reported in existing databases. A significant finding of our study is the identification of five such novel variants. Three of these are pathogenic or likely pathogenic based on standardized interpretation guidelines.²⁵ In addition to revealing new pathogenic variants, comprehensive gene sequencing reveals novel variants, and currently undefinable variants, classified as variants of uncertain clinical significance.

In all patients referred for thrombotic microangiopathy genetic testing, variants of uncertain clinical significance represent the largest category of single-nucleotide variants identified at 22% (15/73). However, this is significantly lower than the rate of variants of uncertain clinical significance previously reported by Bu *et al.*³ of 35% (68/193) ($P=0.026$). A portion of this discrepancy may reflect the absence of *CFHR5* and *PLG* in our reportable gene set. However, this discordance may be further attributed to differences in criteria applied to classify variants between the two studies. In the current study, comparison of variant classifications showed significantly higher GERP++ scores and lower minor allele frequency in pathogenic/likely pathogenic variants compared with variants of uncertain clinical significance. Similarly, *in silico* prediction tools showed significant differences between these two groups.

In the current series, patients referred for thrombotic microangiopathy genetic sequencing most commonly harbor single-nucleotide variants in *CFH*, but variants identified in *CD46* are most likely to be classified as pathogenic owing to the higher incidence of splice-site variants identified in the gene. Homozygous *CFHR3-CFHR1* deletions are identified in 12% of patients, indicating an increased risk for the development of anticomplement factor H antibodies.⁴⁵

Resolving variants of uncertain clinical significance is challenging for clinicians owing to less than definitive information on the variant and its application to patient management. In such settings, discussions with a clinical team composed of molecular pathologists, geneticists, genetic counselors, and nephrologists may be useful. Current recommendations indicate that variants of uncertain clinical significance should not be used in clinical decision making.²⁵ Therefore, to further define associations between gene variants and pathogenesis, genetic findings need to be correlated with functional studies, clinical outcome, pathology findings, familial cosegregation, and treatment response.²⁵ Renal genetic analysis is challenging due to incomplete penetrance, variable expressivity, and complex modes of inheritance. It is anticipated that as more laboratories describe genetic variants, further studies will be performed to illuminate their significance.

In addition to follow-up analyses, our data suggest a need for expanded variant curation resources in the setting of renal disease including a centralized database to deposit annotated disease-associated variants identified as part of routine clinical care. Presently, the ClinVar database serves as a public archive documenting the report of relationships between human phenotype and genetic variation. However, the paucity of renal disease-associated variation makes this resource limited in function. Expansion of the ClinVar database and other renal genetic knowledgebases would be invaluable to assist laboratories in assigning significance to individual variants with little published information. Such a database needs accurate clinical information in addition to variant information and could serve as a source for other investigators to use in attempts to further characterize unique genetic findings.

New disease gene associations continue to emerge. Chong *et al.*⁴⁶ report 915 new disease genes over the past 4 years.⁴⁶ It is therefore important to design a test readily adaptable to new discoveries without incurring significant cost and time. Using a unique panel-based next-generation sequencing test requires revalidation for each new gene target added. In contrast, building a test on an exome backbone allows for simpler and more rapid validation of new genes, making this approach nimble and cost-effective. Using this approach, clinically relevant genes are reported in the medical record, while the remaining exome sequence is captured and bioinformatically masked. Thus, these data can be

leveraged as new biologic gene targets emerge. Under appropriate consent/human research protections, these data also provide a rich resource of research material to investigate additional genes associated with thrombotic microangiopathy and potential genetic modifiers contributing to states of inappropriate complement activation.

The study is limited by the small sample size, an inherent problem when studying rare diseases such as atypical hemolytic uremic syndrome. Since many of the cases are referred from outside institutions, complete clinical data are not available for majority of patients. Reliance on the referring clinician's diagnostic impression may artificially lower the diagnostic yield. Nonetheless, this reflects the results clinicians can expect in actual clinical practice.

This study describes the use of clinical exome-based next-generation sequencing testing with targeted bioinformatics analysis and reporting for routine care of patients referred for thrombotic microangiopathy genetic testing. Our results highlight the inherent difficulty in applying the current ACMG/AMP guidelines in interpreting single-nucleotide variants due to the paucity of available data in the renal disease setting. The results show a lower diagnostic yield than previously reported and a high number of variants of uncertain clinical significance. The decrease in diagnostic yield appears to be due to the absence of variants of uncertain clinical significance for inclusion as a positive diagnostic finding. The current study demonstrates that exome-based next-generation sequencing testing in patients with thrombotic microangiopathies can be applied in a clinical setting and provide meaningful results to assist in clinical care of patients.

Acknowledgments

We thank Kidney Translational Research Core (KTRC), partly supported by DK079333, for providing samples for validation testing. This work was previously presented at the United States and Canadian Academy of Pathology Annual Meeting in Seattle, WA in March of 2016. All authors reviewed the data and participated in preparation of the manuscript and approved the final version.

Disclosure/conflict of interest

JDP is a cofounder of PierianDx JWH is a paid consultant for PierianDx, and JPG is a member of the Alexion Genetic Testing Advisory Board.

References

- 1 Nester CM, Barbour T, de Cordoba SR, *et al*. Atypical aHUS: state of the art. *Mol Immunol* 2015;67:31–42.

- 2 George JN, Nester CM. Syndromes of thrombotic microangiopathy. *N Engl J Med* 2014;371:654–666.
- 3 Bu F, Borsa NG, Jones MB, *et al*. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. *J Am Soc Nephrol* 2016;27:1245–1253.
- 4 Noris M, Caprioli J, Bresin E, *et al*. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. *Clin J Am Soc Nephrol* 2010;5:1844–1859.
- 5 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361:1676–1687.
- 6 Greenbaum LA. Atypical hemolytic uremic syndrome. *Adv Pediatr* 2014;61:335–356.
- 7 Fremeaux-Bacchi V, Fakhouri F, Garnier A, *et al*. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. *Clin J Am Soc Nephrol* 2013;8:554–562.
- 8 Bu F, Borsa N, Gianluigi A *et al*. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. *Clin Dev Immunol* 2012;2012:370426.
- 9 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. *Semin Nephrol* 2013;33:508–530.
- 10 Stokman MF, Renkema KY, Giles RH, *et al*. The expanding phenotypic spectra of kidney diseases: insights from genetic studies. *Nat Rev Nephrol* 2016;12:472–483.
- 11 Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. *Nat Rev Nephrol* 2016;12:133–146.
- 12 Prakash S, Gharavi AG. Diagnosing kidney disease in the genetic era. *Curr Opin Nephrol Hypertens* 2015;24:380–387.
- 13 Fakhouri F, Fila M, Provot F, *et al*. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. *Clin J Am Soc Nephrol* 2016;12:50–59.
- 14 Bu F, Maga T, Meyer NC, *et al*. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2014;25:55–64.
- 15 Taylor CM, Machin S, Wigmore SJ, *et al*. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. *Br J Haematol* 2010;148:37–47.
- 16 Campistol JM, Arias M, Ariceta G, *et al*. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. *Nefrologia* 2015;35:421–447.
- 17 Loirat C, Fakhouri F, Ariceta G, *et al*. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. *Pediatr Nephrol* 2016;31:15–39.
- 18 Wetterstrand K. Sequencing costs: data from the NHGRI genome sequencing program (GSP). Available at: <https://www.genome.gov/sequencingcostsdata/> (last accessed 9 August 2016).
- 19 Braun DA, Schueler M, Halbritter J, *et al*. Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity. *Kidney Int* 2016;89:468–475.
- 20 Mori T, Hosomichi K, Chiga M, *et al*. Comprehensive genetic testing approach for major inherited kidney diseases, using next-generation sequencing with a custom panel. *Clin Exp Nephrol* 2016;21:63–75.

- 21 Moriniere V, Dahan K, Hilbert P, *et al*. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. *J Am Soc Nephrol* 2014;25:2740–2751.
- 22 Chatterjee R, Ramos E, Hoffman M, *et al*. Traditional and targeted exome sequencing reveals common, rare and novel functional deleterious variants in RET-signaling complex in a cohort of living US patients with urinary tract malformations. *Hum Genet* 2012;131:1725–1738.
- 23 Liapis H, Jain S. The interface of genetics with pathology in alport nephritis. *J Am Soc Nephrol* 2013;24:1925–1927.
- 24 Maga TK, Nishimura CJ, Weaver AE *et al*. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. *Hum Mutat* 2010;31:E1445–E1460.
- 25 Richards S, Aziz N, Bale S, *et al*. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424.
- 26 Schouten JP, McElgunn CJ, Waaijer R, *et al*. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. *Nucleic Acids Res* 2002;30:e57.
- 27 Moore I, Strain L, Pappworth I, *et al*. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. *Blood* 2010;115:379–387.
- 28 Aziz N, Zhao Q, Bry L, *et al*. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. *Arch Pathol Lab Med* 2015;139:481–493.
- 29 Sharma MK, Phillips J, Agarwal S, *et al*. Clinical genomicist workstation. *AMIA Jt Summits Transl Sci Proc* 2013;2013:156–157.
- 30 Lek M, Karczewski KJ, Minikel EV, *et al*. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016;536:285–291.
- 31 Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* 2011;27:2987–2993.
- 32 Li H, Handsaker B, Wysoker A, *et al*. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 2009;25:2078–2079.
- 33 Davydov EV, Goode DL, Sirota M, *et al*. Identifying a high fraction of the human genome to be under selective constraint using GERP++. *PLoS Comput Biol* 2010;6:e1001025.
- 34 Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PLoS ONE* 2012;7:e46688.
- 35 Caprioli J, Castelletti F, Bucchioni S, *et al*. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. *Hum Mol Genet* 2003;12:3385–3395.
- 36 Mohlin FC, Nilsson SC, Levart TK, *et al*. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. *Mol Immunol* 2015;65:367–376.
- 37 Neumann HP, Salzmann M, Bohnert-Iwan B, *et al*. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. *J Med Genet* 2003;40:676–681.
- 38 Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, *et al*. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. *Am J Hum Genet* 2001;68:478–484.
- 39 Sartz L, Olin AI, Kristoffersson AC, *et al*. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. *J Immunol* 2012;188:2030–2037.
- 40 Le Quintec M, Lionet A, Kamar N, *et al*. Complement mutation-associated *de novo* thrombotic microangiopathy following kidney transplantation. *Am J Transplant* 2008;8:1694–1701.
- 41 Bienaime F, Dragon-Durey MA, Regnier CH, *et al*. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. *Kidney Int* 2010;77:339–349.
- 42 Schramm EC, Roumenina LT, Rybkine T, *et al*. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. *Blood* 2015;125:2359–2369.
- 43 Delvaeye M, Noris M, De Vriese A, *et al*. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. *N Engl J Med* 2009;361:345–357.
- 44 Lemaire M, Fremeaux-Bacchi V, Schaefer F, *et al*. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. *Nat Genet* 2013;45:531–536.
- 45 Dragon-Durey MA, Loirat C, Cloarec S, *et al*. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. *J Am Soc Nephrol* 2005;16:555–563.
- 46 Chong JX, Buckingham KJ, Jhangiani SN, *et al*. The genetic basis of mendelian phenotypes: discoveries, challenges, and opportunities. *Am J Hum Genet* 2015;97:199–215.